相关实验视频

Updated: May 30, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

阐明EGFR突变NSCLC的潜力,并确定其多位抑制剂

Anakha D Rajeeve^1,2, Ramasamy Yamuna^3,4, P K Krishnan Namboori^5,6,7,8

¹Department of Chemistry, Amrita School of Physical Sciences Coimbatore, Amrita Vishwa Vidyapeetham, Coimbatore, India.

Scientific reports

|January 29, 2025

概括

黄素和CB[2]UN对EGFR突变非小细胞肺癌 (NSCLC) 蛋白具有强烈的结合和稳定性. 这项计算研究强调了它们作为治疗肺癌治疗的治疗剂的潜力.

科学领域:

计算化学是一种计算化学.
分子建模分子建模
药物发现药物发现

背景情况:

肺癌是全球癌症死亡的主要原因之一.
表皮生长因子受体 (EGFR) 基因突变在非小细胞肺癌 (NSCLC) 中很常见.
黄素和CB[2]UN具有与药物输送相关的药用特性.

研究的目的:

通过十二角计算方法研究黄素和CB[2]UN在控制EGFR突变性NSCLC方面的疗效.
评估黄素和CB[2]UN与EGFR突变NSCLC蛋白质的结合亲和力和稳定性.

主要方法:

进行了分子对接研究,以评估联体蛋白相互作用.
分子动力学模拟 (50 ns) 使用RMSD,RMSF,Rg和SASA评估了动力稳定性.
通过MMPBSA/MMGBSA和KDeep计算,确定了热力学稳定性和绝对结合亲和度.

主要成果:

黄素和CB[2]UN对EGFR突变NSCLC蛋白 (分别为2ITX和2ITV) 具有强烈的结合亲和力.
分子动力学模拟表明了蛋白质-连接体复合体的动力稳定性.
热力学分析证实了稳定性,KDeep的计算显示了显著的结合能 (-2ITX-CUR的6.13 kcal/mol和-2ITV-CB的-5.26 kcal/mol).

结论:

十二角计算策略表明,2ITX-CUR和2ITV-CB[2]UN复合体具有较高的结合亲和度和优异的稳定性.
黄素和CB[2]UN显示为EGFR突变NSCLC的潜在治疗剂.

关键词:

黄瓜比图里尔是一种.十二角战略是一个十二角战略.欧洲农业基金会 (EGFR) 是一个.肺癌是一种肺癌.分子动力学模拟模型多位抑制剂多位抑制剂

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...